©2022 Stanford Medicine
High Dose Steroid Therapy to Treat Flares in Patients With Inflammatory Bowel Disease (IBD)
Trial ID: NCT05587673
This study will examine whether delivery of high dose steroids, directly into the inflamed bowel via its arterial blood supply, will be better for treating uncontrolled flares of inflammatory bowel disease in patients compared to conventional intra-venous or oral administration of this drug. Patients aged 4-25 years of age will be recruited. In this study, we hope to also learn how this directed steroid delivery during an active flare will improve patient symptoms as well as the appearance of inflamed segments of bowel determined by imaging or biopsy (i.e. at the time of endoscopy). Additional data will determine how the blood vessels in the bowel affect, and potentially even drive the mechanisms, of inflammatory bowel disease.
A Pilot Study Investigating the Feasibility and Efficacy of Locoregional Intra-arterial Administration of Methylprednisolone as a Bridge Therapy to Treat Symptomatic Flares in Inflammatory Bowel Disease.
- Patients with newly diagnosis of inflammatory bowel disease (IBD) or patients who have
an established diagnosis of IBD and are experiencing an acute flare which is not being
controlled with first line therapy
- Patients present with typical IBD symptoms which will include, but are not limited to,
abdominal pain, loss of appetite, rectal bleeding, diarrhea, obstruction, or passage
- Patients referred by the GI team.
- Patients (or guardians/parents) must be able and willing to give consent (or assent
where applicable) and be able to attend all study visits.
- Patients with MR unsafe metallic implants that will not be able to undergo the MRI
portion of the study.
- Patients with renal function impairment (GFR < 45 mL/min) preventing contrast
- Patients with contrast allergy.